Contribution of extensive biological work-up in patients with venous or arterial thrombotic events;INTERET D'UNE EXPLORATION BIOLOGIQUE APPROFONDIE AU COURS DES THROMBOSES VEINEUSES OU ARTERIELLES

Presse Medicale

Volumn 25, Issue 11, 1996, Pages 531-536

  Tazi, Z ^a   Cacoub, P ^a   Koskas, F ^a   Chabanel, A ^b   Chadefaux Vekemans, B ^c   Horellou, M H ^b   Viard, J P ^c   Piette, J C ^a   Kieffer, E ^a   Godeau, P ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b HÔTEL DIEU   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; CARDIOLIPIN ANTIBODY; GLYCOPROTEIN; HOMOCYSTEINE; LIPOPROTEIN; PROTEIN C; PROTEIN S; APOLIPOPROTEIN; BETA2 GLYCOPROTEIN 1; PHOSPHOLIPID ANTIBODY;

ADOLESCENT; ADULT; AGED; ANTIBODY PRODUCTION; ARTERY THROMBOSIS; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; ERYTHROCYTE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; BLOOD; ERYTHROCYTE AGGREGATION; EVALUATION; IMMUNOLOGY; MIDDLE AGED; RECURRENT DISEASE; RETROSPECTIVE STUDY; RISK FACTOR; THROMBOSIS;

ADOLESCENT; ADULT; AGED; ANTIBODIES, ANTICARDIOLIPIN; ANTIBODIES, ANTIPHOSPHOLIPID; APOLIPOPROTEINS; BETA 2-GLYCOPROTEIN I; ERYTHROCYTE AGGREGATION; EVALUATION STUDIES; FEMALE; GLYCOPROTEINS; HOMOCYSTEINE; HUMANS; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; THROMBOSIS;

EID: 0030606474     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Frederick SE Hypercoagulabilité en chirurgie vasculaire. Ann Chir Vasc 1992 ; 6 313-19.
2. Viard JP, Amoura Z, Bach JF. Association of anti-β2 glycoprotein 1 antibodies with lupus-type circulating anticoagulant and thrombosis in systemic lupus erythematosus. Am J Med 1992 ; 93:181-6.
3. Refsum H, Helland S, Uelland PM Radioenzymatic determination of homocysteine in plasma and urine Clin Chem 1985 ; 31:624-7
4. Chadefaux B, Caudé M, Hamet M, Aupetit J, Kamoun P Rapid determination of total homocysteine in plasma. Clin Chem 1989 ; 35:2002.
5. Steinmetz J, Tarallo P, Fournier B et al. Valeurs de références de la lipoprotéine (a) dans une population française. Presse Med 1994 , 23:1695-8.
6. Boers GHJ, Smals AGH, Trijbels FJM et al Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med 1985 ; 313:709-15
7. Verhoef P, Hennekens CH, Malinow MR, Kok FJ, Willett WC, Stampfer MJ. A prospective study of plasma homocyst(e)in and risk of ischemic stroke. Stroke 1994 ; 25:1924-30.
8. Genest JJ, McNamara JR, Upon B, Salem DN, Ordovas JM, Schaefer EJ Prevalence of familial hyperhomocyst(e)inemia in men with premature coronary artery disease. Arterio Thromb 1991 ; 11:1129-36
9. Stampfer JM, Malinow R, Willett CW. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992 ; 268:877-81
10. Aronson DC, Onkenhout W, Raben AMTJ, Oudenhoven LFIJ, Brommer EJP, VanBockel JH. Impaired homocysteine metabolism: a risk factor in young adults with atherosclerosic arterial occlusive disease of the leg Br J Surg 1994 ; 81:1114-18.
11. Malinow MR, Kang SS, Taylor LM et al. Prevalence of hyperhomocyst(e) inemia in patients with peripheral arterial occlusive disease. Circulation 1989 ; 79:1180-8.
12. Coull BM, Malinow MR, Beamer N, Sexton G, Nordt F, DeGarmo P. Elevated plasma homocyst(e)ine concentration as a possible independent risk factor for stroke. Stroke 1990, 21:572-6.
13. Den Hejjer J, Blom H, Gerrits WBJ et al. Is hyperhomocysteinemia a risk factor for recurrent venous thrombosis? Lancet 1995 ; 345:882-5
14. Clarke R, Daly L, Robinsson K et al Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991 ; 324:1149-55
15. Malinow MR Hyperhomocyst(e)inemia, a common and easily reversible risk factor for occlusive atherosclerosis Circulation 1990 ; 81:2004-6.
16. Van den Berg M, Franken DG, Boers GHJ et al. Combined vitamin B6 plus folic acid therapy in young patients with arteriosclerosis and hyperhomocysteinemia. J Vasc Surg 1994 ; 20:933-40.
17. Roubey RAS. Antoantibodies to phospholipid-binding plasma proteins, a new view of lupus anticoagulants and other "antiphospholipid" autoantibodies Blood 1994 ; 84:2854-67.
18. Karmochkine M, Piette JC, Mazoyer E et al. Anticorps antiphospholipides: cause des thromboses ou épiphénomène ? Presse Med 1995 ; 24:267-70
19. Telmon N, Ecoiffier M, Cleostrate MH, Oksman F, Adoue D. Place des anticorps anticardiolipine Presse Med 1994 ; 23:765.
20. Vianna JL, Khamashta MA, Ordi-Ros J et al. Comparison of the primary and secondary antiphospholipid syndrome: European multicenter study of 114 patients. Am J Med 1994 ; 96:3-9.
21. Gharavi AE, Sammaritano LR, Wen J. Characteristics of human immunodeficiency virus and chlorpromazine induced antiphospholipid antibodies: effect of β2-glycoprotein I on binding to phospholipid. J Rheumatol 1994 ; 21:1-9.
22. Alarçon-Segovia D, Delezé M, Oria CV et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients. Medicine 1989 ; 68:353-65.
23. Ahn SS, Kalunian K, Rosove M, Moore W. Postoperative thrombotic complications in patients with the lupus anticoagulant: Increased risk after vascular procedures J Vasc Surg 1988 ; 7:749-56.
24. Love PE, Santoro SA Antiphospholipid antibodies: Anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Ann Intern Med 1990 ; 112:682-98
25. Bancsi LF, Van Der Linden IK, Bertina RM β2-glycoprotein I deficiency and risk of thrombosis Thromb Haemost 1992 ; 67:649-50.
26. Murai A, Miyahara T, Fujimoto N, Matsuda M, Kameyama M Lp(a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction Atherosclerosis 1986 ; 52:199-204.
27. Sandkamp M, Funke H, Schulte H, Kohler E, Assmann G. Lipoprotein (a) is an independent risk factor for myocardial infarction at a young age. Clin Chem 1990 ; 36:20-3
28. Kostner GM, Avogaro P, Cazzolato G, Marth E, Bittolo-Bon G, Gunici GB. Lipoprotein Lp(a) and the risk for myocardial infarction. Atherosclerosis 1981 ; 33:51-61.
29. Zenker G, Költringer P, Boné G, Niederkorn K, Pfeiffer K, Jurgens G. Lipoprotein(a) as a strong indicator for cerebrovascular disease. Stroke 1986 ; 17 942-5.
30. Chapman J, Guerin M. La lipoprotéine Lp(a) et la CETP (protéine de transfert des esters de cholesterol): apports des souris transgéniques. Bull Acad Natl Med 1994 ; 178:427-36.
31. Loscalzo J, Weinfeld M, Fless GM, Scanu AM. Lipoprotein (a), fibrinbinding, and plasminogen activation. Arteriosclerosis 1990 ; 10:240-5.
32. Miles LA, Fless GM, Levin EG, Scanu AM, Plow EF. A potential basis for the thrombotic risks associated with Lipoprotein (a). Nature 1989 ; 339:301-3.
33. Patthy L. Evolution of the proteases of blood coagulation and fibrinolysis by assembly from modules. Cell 1985 ; 41:657-63.
34. Hajjar KA, Gavish D, Breslow JL, Nachman RL Lipoprotein (a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 1989 ; 339:303-5.
35. Carlson LA, Hamsten A, Asphind A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Int Med 1989 ; 226:271-6.
36. Briett E, Engesser L, Brommer EJP. Thrombophilia: its causes and a rough estimate of its prevalence Thromb Haemost 1987 ; 58: 39 (abstr)
37. Scharrer I, Hack-Wunderle V, Heyland H, Kuhn C. Incidence of defective t-PA release in 158 unrelated young patients with venous thrombosis in comparison to PC, PS. ATIII, fibrinogen and plasminogen deficiency Thromb Haemost 1987 ; 58 7 (abstr).
38. Israels SJ, Seshia SS. Childhood stroke associated with protein C or S deficiency. J Pediatr 1987 ; 111:562-4.
39. Dhalback B, Carlson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C. Proc Natl Acad Sci USA 1993 ; 90 1004-8.
40. Bertina RM, Koeleman BPC, Koster T. Mutation in blood coagulation Factor V associated with resistance to activated protein C. Nature 1994 ; 369:64-7.
41. Samama MM. Une nouvelle cause de thrombophilie héréditaire : La résistance à la protéine C activée. J Mal Vasc 1994 ; 19:173-4.
42. Trossaërt M, Conard J, Horellou MH, Samaha M, Elalamy I, Samama MM. Résistance à la protéine C activée dans les accidents thrombo-emboliques veineux Fréquence et manifestations cliniques. Presse Med 1995 ; 24:209-12.
43. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletichi JP. Mutation in the gene coding for coagulation factor V and risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995 ; 332:912-17.
44. Chabanel A, Horellou MH, Conard J, Samama MM. Red blood cells aggregability in patients with a history of leg vein thrombosis, influence of post-thrombotic treatment. Br J Haematol 1994 ; 88 : 174-9.
45. Eldrup-Jorgensen J, Flanigan DP, Brace L et al. Hypercoagulable states and lower limb ischemia in young adults. J Vasc Surg 1989 ; 9:334-41.